Filtern
Volltext vorhanden
- ja (24)
Gehört zur Bibliographie
- ja (24)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (24)
Schlagworte
- B cells (3)
- adalimumab (3)
- rheumatoid arthritis (3)
- scleroderma (3)
- systemic sclerosis (3)
- Autologous hematopoietic stem cell transplantation (2)
- Systemic sclerosis (2)
- Th17 (2)
- antirheumatic agents (2)
- inflammation (2)
- memory B cells (2)
- regression analysis (2)
- treatment outcome (2)
- B cell culture (1)
- CMV reactivation (1)
- CP-690,550 (1)
- Clinical remission (1)
- DAS28 (1)
- DMARD (1)
- Drug-free remission (1)
- GCA (1)
- GRAID (1)
- Grave’s disease (1)
- HAQ (1)
- Infectious complications (1)
- Interleukin-10 (1)
- Medizin (1)
- Memory B cells (1)
- PMR (1)
- PROM’s (1)
- PU.1 (1)
- Rheumatoid Arthritis (1)
- Rituximab (1)
- S100A8/S100A9 (1)
- Scleroderma (1)
- Sjögren’s syndrome (1)
- Synovitis (1)
- T cells (1)
- Th9 (1)
- Tregs (1)
- Validation (1)
- [18F]FDG PET/CT (1)
- adverse events (1)
- arthritis (1)
- autoimmune disease (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous hematopoietic stem cell transplantation (1)
- autologous stem cell transplantation (1)
- bile (1)
- c-reactive protein (1)
- calprotectin (1)
- care (1)
- chemokines (1)
- cirrhosis (1)
- clinical-practice (1)
- common variable immunodeficiency (1)
- common variable immunodeficiency (CVID) (1)
- contrast-enhanced ultrasound. (1)
- cytokines (1)
- cytotoxic T cells (1)
- discordance (1)
- disease comorbidities (1)
- disease-activity score (1)
- engraftment syndrome (1)
- fatigue (1)
- fever (1)
- genital warts (1)
- giant cell arteritis (1)
- health-assessment questionnaire (1)
- hepatitis C virus (1)
- human papillomavirus (1)
- immune cells (1)
- immunophenotyping (1)
- immunosuppression (1)
- inborn errors of immunity (IEIs) (1)
- inflammation marker (1)
- interleukin-9 (1)
- iohexol (1)
- janus kinase inhibitor (1)
- kidney function (1)
- liver diseases (1)
- methotrexate (1)
- methylation (1)
- minimally important difference (1)
- modified Rodnan skin score (mRSS) (1)
- mycophenolate (1)
- naïve B cells (1)
- neurology (1)
- physicians (1)
- plasma clearance (1)
- polymyalgia rheumatica (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (1)
- renal function (1)
- renal perfusion (1)
- reported outcomes (1)
- rheumatoid (1)
- rheumatoid arhritis (1)
- risk factor analysis (1)
- rituximab (1)
- serum creatinine (1)
- suppression (1)
- tocilizumab (1)
- tocilizumab (IL-6 inhibitor) (1)
- validation (1)
- vasculature (1)
- vasculitis (1)
- γδ T cells (1)
Institut
- Medizinische Klinik und Poliklinik II (24)
- Kinderklinik und Poliklinik (3)
- Neurologische Klinik und Poliklinik (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Pathologisches Institut (1)
Background
Assessing serological inflammation is difficult in tocilizumab (TCZ)-treated rheumatoid arthritis (RA) patients, as standard inflammation parameters, like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are influenced by interleukin-6-receptor inhibition. Calprotectin in the serum, also named S100A8/S100A9, might be a more useful inflammation parameter in TCZ-treated patients.
Methods
Sixty-nine RA patients taking TCZ were included. Serum-calprotectin levels were assessed, as well as ESR, CRP, need for a change in disease-modifying anti-rheumatic drugs due to RA activity (= active RA), and the RA clinical disease activity score (CDAI). Forty-five RA patients taking tumor-necrosis factor-inhibitors (TNFi) were investigated for the same parameters.
Results
TCZ-treated patients with active RA had higher calprotectin values than not active RA patients (4155.5 [inter quartile range 1865.3–6068.3] vs 1040.0 [676.0–1638.0] ng/ml, P < 0.001). A calprotectin cut-off value of 1916.5 ng/ml resulted in a sensitivity and specificity of 80.0 %, respectively, for the detection of RA disease activity. Calprotectin values correlated with CDAI-scores (r = 0.228; P = 0.011). ESR and CRP were less suitable to detect RA activity in TCZ-treated patients. Also TNFi-treated patients with active RA had higher calprotectin values compared to not active RA (5422.0 [3749.0–8150.8] vs 1845.0 [832.0–2569.0] ng/ml, P < 0.001). The calprotectin value with the best sensitivity and specificity for detecting RA activity was 3690.5 ng/ml among TNFi-treated patients.
Conclusion
Calprotectin in the serum can be a useful inflammation parameter despite TCZ-treatment.